Klisovic RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al. A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. Cancer 2021 Aug 3. doi: 10.1002/cncr.33796.
PMID: 34343354